Lantus, Insulin Glargine News

RESEARCH DESIGN AND METHODS: This 28-week parallel-group study randomized 233 insulin-naive patients with HbA values>/=8.0% on>1,000 mg/day metformin alone or in combination with other OADs.

A recent study, published in the December issue of Mayo Clinic Proceedings , demonstrates new survival data for the blood disorder myelofibrosis.

Type 2 diabetes and obesity are linked to an increased risk of certain cancers. Recently published studies suggested that insulin glargine , may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications.

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.

Shedding Light on the Co-morbidities of Diabetes The Complications of Having Rheumatoid Arthritis and Diabetes Insulin shots vs insulin pump 11/18/09 yoli Topics: Insulin shots vs insulin pump I have been a diabetic for 10 years.

The social policy ministry is expected to rectify a long-standing, and painful issue for sufferers of diabetes.

Privately held Wellstat Therapeutics Corp. stands to gain up to $350 million, including an undisclosed up-front payment, in exchange for global rights to its Type II diabetes oral insulin sensitizer PN2034 and related compounds in a development and commercialization deal with Sanofi-Aventis Group SA, which sought the licensing agreement to beef up ...

Paris, October 21, 2009 Sanofi-aventis and Wellstat Therapeutics Corporation announced today a global licensing agreement on PN2034, a novel oral first-in-class, insulin sensitizer, for the treatment of Type II Diabetes.

A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes , demonstrated that the Novo Nordisk long-acting insulin Levemir was not associated with any increase in the incidence of cancer when compared to human insulin .

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilar insulins and insulin analogues stand to erode $6.1B in brand sales in the U.S. and Europe by 2018, saving healthcare systems $3.8B in the process.

Provincial drug plans often follow the coverage recommendations of Canada's Common Drug Review board.

Findings demonstrate that Type 2 diabetes patients starting insulin treatment with once-daily injection of NovoMix 30 achieve a significantly greater HbA reduction compared to patients starting with a daily injection of insulin glargine.

Sanofi-aventis announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus compared to twice-daily insulin detemir.

Novo Nordisk's Levemir was not associated in any increase in incidence of cancer when compared with human insulin in studies including some 9,000 patients, according to a new analysis released on Thursday.

NEW YORK Possible links between a popular brand of insulin and cancer have prompted doctors to investigate, according to published reports.

Doctors will try to unravel possible ties between diabetes treatments and cancer this week after studies indicated that medicines used by millions of people may leave some vulnerable to tumors.

French drugmaker Sanofi-Aventis said Tuesday that it is planning to undertake methodologically robust research that will contribute to the scientific resolution of the debate over insulin safety, including insulin analogs and its Lantus drug.

Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial Export JAMA , Vol.

"What a wonderful book! Diabetes can feel confusing and overwhelming, but it doesn't have to be a ' especially thanks to books like this." a ' Dr.

Thursday, 24 September 2009, 11:29 am Press Release: Ministry of Health No conclusive evidence linking insulin glargine to higher cancer risk Medicines regulatory authorities in New Zealand have found no conclusive evidence that the use of insulin glargine is associated with increased risk of developing cancer, saying findings of recent studies may ...